公开(公告)号：US6140363A

公开(公告)日：2000-10-31

申请号：US312405

申请日：1999-05-14

申请人： Eun Mi Hur ,  Young Bong Choi ,  Changwon Park ,  Jongsung Lee ,  Dongsu Park ,  Yungdae Yun ,  Keun Hyeung Lee ,  Jong-Eun Oh ,  Soon Choul Ahn ,  Hyun Sun Lee ,  Jong Sok Ahn ,  Soo Il Jung

发明人： Eun Mi Hur ,  Young Bong Choi ,  Changwon Park ,  Jongsung Lee ,  Dongsu Park ,  Yungdae Yun ,  Keun Hyeung Lee ,  Jong-Eun Oh ,  Soon Choul Ahn ,  Hyun Sun Lee ,  Jong Sok Ahn ,  Soo Il Jung

IPC分类号： A61K45/00 ,  A61K31/00 ,  A61K31/216 ,  A61K36/18 ,  A61P1/16 ,  A61P7/02 ,  A61P9/10 ,  A61P25/00 ,  A61P25/28 ,  A61P29/00 ,  A61P31/04 ,  A61P31/18 ,  A61P35/02 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  A61P43/00 ,  A61K31/235

CPC分类号： A61K31/00

摘要： The present invention relates to use of rosmarinic acid and/or derivatives thereof as immunosuppressive agents and/or as inhibitor of SH2 domain function. Disclosed in the present invention is that rosmarinic acid and derivatives thereof specifically inhibit the binding of ligand peptides to Lck SH2 domain, disturb the Lck-mediated signal transduction in T cells, also inhibit cytoline gene expression, and suppress immune responses in the transplanted tissue. These activities of rosmarinic acid and derivatives thereof support their applicability to treatment, prevention and/or diagnosis of graft rejection, GVHD, autoimmune diseases, inflammatory diseases, etc.

摘要翻译： 本发明涉及迷迭香酸和/或其衍生物作为免疫抑制剂和/或作为SH2结构域功能的抑制剂的用途。 在本发明中公开的是，迷迭香酸及其衍生物特异性抑制配体肽与Lck SH2结构域的结合，扰乱T细胞中的Lck介导的信号转导，也抑制细胞基因表达，并抑制移植组织中的免疫应答。 迷迭香酸及其衍生物的这些活性支持其适用于治疗，预防和/或诊断移植排斥反应，GVHD，自身免疫疾病，炎性疾病等。

公开(公告)号：US06770457B1

公开(公告)日：2004-08-03

申请号：US09701265

申请日：2000-11-27

申请人： Weon Kyoo You ,  Seung Ho So ,  Byung Cheul Ahn ,  Hyosil Lee ,  Soo-Il Jung ,  Young jo Kim ,  Jong Hyuk Lee ,  Yong-Kil Hong ,  Young Ae Joe ,  Soo-Ik Chang

发明人： Weon Kyoo You ,  Seung Ho So ,  Byung Cheul Ahn ,  Hyosil Lee ,  Soo-Il Jung ,  Young jo Kim ,  Jong Hyuk Lee ,  Yong-Kil Hong ,  Young Ae Joe ,  Soo-Ik Chang

IPC分类号： C12P2106

CPC分类号： C12N9/6435 ,  A61K38/00 ,  C07K14/475 ,  C12Y304/21007

摘要： The present invention relates to process of purifying the angiogensis inhibitor proteins expressed in E. coli and to the use of recombinant kringle 1-3 (; greenstatin) purified by the above process as a angiogenesis inhibitor and an anticancer agent. Particularly, according to the process of purifying the protein, the angiogenesis inhibitor proteins overexpressed are solubilized, refolded, and purified as a pure and active form. The greenstatin purified by the process specifically suppresses endothelial cell proliferation, anaiogenesis, and the growth of lung cancer, skin cancer, and brain tumor. Therefore, the process of this invention is applicable to the mass-production of angiogenesis inhibitor proteins such as greenstatin which is useful for the treatment of glaucoma, retinopathy, and cancers.

摘要翻译： 本发明涉及纯化在大肠杆菌中表达的血管紧张素抑制剂蛋白质的方法，以及通过上述方法纯化的重组三环酮1-3（;绿色抑制素）作为血管生成抑制剂和抗癌剂的用途。 特别地，根据纯化蛋白质的过程，过表达的血管生成抑制蛋白被溶解，重折叠并纯化为纯的和活性的形式。 通过该方法纯化的绿素抑制剂特异性抑制内皮细胞增殖，发生发生，以及肺癌，皮肤癌和脑肿瘤的生长。 因此，本发明的方法适用于批量生产可用于治疗青光眼，视网膜病变和癌症的绿调素抑制剂等血管发生抑制蛋白。